Inflation Reduction Act Pharmacy Provisions – Implications and Other Changes
Introduction This is the final article in a three-part series[1],[2] discussing the impact of the Inflation Reduction [...]
Introduction This is the final article in a three-part series[1],[2] discussing the impact of the Inflation Reduction [...]
How are insurers coping with the increased demand for multi-use drugs like Wegovy and Ozempic? In an article [...]
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, [...]
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin [...]
Introduction There is a coming wave of changes arriving soon to the pharmacy market in the form of [...]